NEXPOVIO

This brand name is authorized in Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug NEXPOVIO contains one active pharmaceutical ingredient (API):

1
UNII 31TZ62FO8F - SELINEXOR
 

Selinexor is a nuclear export inhibitor. In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1).
 
Read more about Selinexor

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01XX66 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX66

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1846032, 1846043, 1846054, 1846065
IT Agenzia del Farmaco 049430010, 049430022, 049430034, 049430046, 049430059
LT Valstybinė vaistų kontrolės tarnyba 1092320, 1092321, 1092322, 1092323
PL Rejestru Produktów Leczniczych 100450150

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈